Skip to main content

Advertisement

ADVERTISEMENT

News

News
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Justin Kaner, MD
Conference Coverage
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology

Advertisement

News
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
News
10/04/2024
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once...
10/04/2024
Oncology
News
09/17/2024
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system...
09/17/2024
Oncology

Advertisement

News
08/28/2024
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor...
08/28/2024
Oncology
News
08/28/2024
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a...
08/28/2024
Oncology
News
08/14/2024
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial...
08/14/2024
Oncology

Advertisement

Curtis Lachowiez, MD
Videos
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology

Advertisement